Not Tagged
janssen,bms
['factor xi', 'janssen', 'bristol']
bristol myers squibb and j&amp;j s janssen look to move forward with a phase iii of their factor xia drug in preventing secondary stroke despite missing the goalpost on a composite endpoint, the companies said sunday morning at #esc22. 
The biopharma world is here. Get the industry’s most comprehensive daily news report at https://t.co/rXFyNyZcJs